Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anhui Anke Biotechnology (Group) Co (SZSE:300009) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Anhui Anke Biotechnology (Group) Co Net Margin % Related Terms
Anhui Anke Biotechnology (Group) Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anhui Anke Biotechnology (Group) Co Net Margin % Chart
SZSE:300009 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Anhui Anke Biotechnology (Group) Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anhui Anke Biotechnology (Group) Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anhui Anke Biotechnology (Group) Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Anhui Anke Biotechnology (Group) Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anhui Anke Biotechnology (Group) Co (SZSE:300009) has a Net Margin % of 30.94% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Anhui Anke Biotechnology (Group) Co and its competitors. This is 27% above median its historical median of 24.29. Over the past decade, Anhui Anke Biotechnology (Group) Co's Net Margin % has ranged from 7.27 to 30.17. According to the industry distribution chart, Anhui Anke Biotechnology (Group) Co ranks #99 out of 944 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Anhui Anke Biotechnology (Group) Co's Net Margin % too high?
Anhui Anke Biotechnology (Group) Co's current Net Margin % of 30.94% is 27% above median its 10-year median of 24.29. Over the past 10 years, this metric has ranged from a low of 7.27 to a high of 30.17. Based on the distribution chart, Anhui Anke Biotechnology (Group) Co ranks #99 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anhui Anke Biotechnology (Group) Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anhui Anke Biotechnology (Group) Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anhui Anke Biotechnology (Group) Co ranks #99 out of 944 companies for Net Margin %. This places Anhui Anke Biotechnology (Group) Co in the top 11% of its industry — outperforming the majority of peers. Historically, Anhui Anke Biotechnology (Group) Co's own Net Margin % has ranged from 7.27 to 30.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Anhui Anke Biotechnology (Group) Co and its competitors. Anhui Anke Biotechnology (Group) Co's current Net Margin % is 30.94%, which is 27% above median its own 10-year median of 24.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anhui Anke Biotechnology (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co (SZSE:300009) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.72, compared to a current price of ¥8.73 — trading 18.6% below its estimated fair value. The current Net Margin % is 30.94%, which is 27% above median its 10-year median of 24.29. Anhui Anke Biotechnology (Group) Co's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Anhui Anke Biotechnology (Group) Co (SZSE:300009), the current Net Margin % is 30.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anhui Anke Biotechnology (Group) Co (SZSE:300009) Overvalued in 2026?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co stock appears to be undervalued.
The current stock price of ¥8.73 is trading 18.6% below its estimated GF Value™ of ¥10.72.
GuruFocus considers Anhui Anke Biotechnology (Group) Co to be Modestly Undervalued.
Key valuation signals for SZSE:300009:
Net Margin %: 30.94% (27% above median its 10-year median of 24.29)
GF Value™: ¥10.72 vs. price of ¥8.73 (18.6% below fair value)
No single metric tells the full story. See the SZSE:300009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
90GF Score
Get the complete analysis for SZSE:300009
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300009 has been successfully added to your 
